Stomach-shrinking procedure may help control blood sugar and delay insulin in type 2 diabetes

NCT ID NCT07639684

Not yet recruiting Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a weight-loss procedure called endoscopic sleeve gastroplasty (ESG) can improve blood sugar control and reduce the need for insulin in adults with obesity and type 2 diabetes. Participants have poorly controlled diabetes despite taking standard medications, including GLP-1 drugs. The study will measure changes in blood sugar levels and track serious side effects over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Endoscopic Sleeve Gastroplasty (ESG) with OverStitch Endoscopic Suturing System
What this could lead to: If it works, this could offer a way to improve blood sugar control and reduce or delay the need for insulin in people with obesity and type 2 diabetes.
What could go wrong: This is a small, early-stage trial with no control group, so results may not apply broadly. The procedure carries risks of serious side effects, and weight loss may not be enough to meaningfully change diabetes outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY (BMI>30) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY (BMI>30) TYPE 2 DIABETES MELLITUS (T2D)

More trials for these conditions

Other studies related to the condition(s) this trial covers.